Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 2/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376180 | 0.92 | CPA3 (0.59) | CPA3KEAP1FFAR1MMP1MMP2 | |
| SCHEMBL7052257 | 0.87 | CPA3 (0.60) | CPA3KEAP1FFAR1MMP1MMP2 | |
| SCHEMBL7078968 | 0.87 | MMP2 (0.60) | CPA3MMP12MMP13MMP1MMP2 | |
| SCHEMBL1373606 | 0.85 | CPA3 (0.66) | CPA3KEAP1FFAR1CYP1A2FOLH1 | |
| SCHEMBL7075239 | 0.81 | MMP2 (0.60) | CPA3MMP1MMP2MMP3MMP9 | |
| SCHEMBL7350860 | 0.79 | CPA3 (0.71) | CPA3KEAP1FFAR1MMP3CYP1A2 | |
| SCHEMBL1377036 | 0.79 | CPA3 (0.54) | CPA3KEAP1FFAR1MMP12MMP13 | |
| SCHEMBL7606201 | 0.79 | CPA3 (0.57) | CPA3KEAP1FFAR1MMP1MMP2 | |
| SCHEMBL5863378 | 0.77 | KEAP1 (0.61) | KEAP1FFAR1MMP12MMP13MMP1 | |
| SCHEMBL3963424 | 0.77 | CPA3 (1.00) | CPA3CYP1A2FOLH1CPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2001521512-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2025-04-03 | — | — | US | disclosed |
| CN-116059392-B | Ligand conjugate and application thereof | 同宜医药（苏州）有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CPA3 525/4885KEAP1 3598/4885FFAR1 1147/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CPA3 525/4885KEAP1 3598/4885FFAR1 1147/4885 |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | CPA3 193/4885KEAP1 3129/4885FFAR1 3784/4885 |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | CPA3 1830/4885KEAP1 1012/4885FFAR1 2419/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | CPA3 217/4885KEAP1 2821/4885FFAR1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.